• +41 91 682 20 40
  • info@elixi-int.com
  • Reserved Area
    • Login
    • Register
    • Request Document
    • Send Document
logo
  • Home
  • About Us
  • Services
  • Quality
  • News
  • Case Studies
  • Contact

Let's talk

info@yourwebsite.com
+1 (555) 123-4567

  • Search

Elixi

3 February 2020

FDA approves first drug for treatment of peanut allergy for children


0 Comments4 Minutes

23 January 2020

The combination of lopinavir/ritonavir and interferon-beta- 1b shows good results against the Middle East Respiratory Syndrome Coronavirus (MERS-CoV)


0 Comments3 Minutes

15 January 2020

Enhertu (fam-trastuzumab deruxtecan-nxki), new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies


0 Comments3 Minutes

13 January 2020

Padcev (enfortumab vedotin-ejfv), a new type of therapy to treat advanced urothelial cancer


0 Comments3 Minutes

9 January 2020

Lynparza (olaparib), already licensed for breast and ovarian cancer,it’s set to become the world’s first precision medicine for prostate cancer.


0 Comments2 Minutes

9 January 2020

Phorbiplatin, a new “on-site” activated anti-tumor prodrug that effectively kills cancer cells minimizing damage to normal tissues.


0 Comments5 Minutes

11 December 2019

First generics of Gilenya (fingolimod) capsules for the treatment of relapsing forms of multiple sclerosis (MS)


0 Comments3 Minutes

26 November 2019

MiSight, first contact lens indicated to slow the progression of nearsightedness in children


0 Comments4 Minutes

20 November 2019

Descovy (emtricitabine and tenofovir alafenamide) drug to prevent HIV infection


0 Comments5 Minutes

19 November 2019

Ervebo, First vaccine to protect against Ebola


0 Comments5 Minutes

  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 13

Warning:

A cybersecurity incident is under investigation. Please be carefull with emails or phone calls that correctly mention your name, role, or current transactions. Elixi’s crisis team is working to limit any harmful impact, as the security of our clients’ and suppliers’ data is Elixi’s top priority. For any clarification, you can contact: DPO@elixi-int.com

Si è verificato un evento di sicurezza informatica in corso di analisi. Vi invitiamo a prestare massima attenzione messaggi di posta elettronica o telefonate che citano correttamente il vostro nome, la funzione o operazioni realmente avvenute. Il crisis team di Elixi sta lavorando per limitare ogni conseguenza dannosa, perchè la sicurezza dei dati dei nostri clienti e dei fornitori è la nostra priorità di Elixi. Per ogni chiarimento potete contattare: DPO@elixi-int.com